Retatrutide + Cagrilintide
Exploring the intersection of triple-receptor incretin and glucagon signaling with amylin-associated pathways involved in satiety, metabolic regulation, and energy homeostasis.
What Is Retatrutide + Cagrilintide?
Retatrutide + Cagrilintide is a two-peptide research formulation containing compounds associated with distinct metabolic and neuroendocrine signaling pathways.
Retatrutide (LY3437943) is an investigational peptide agonist of three receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG).
Cagrilintide is a long-acting amylin analog. Amylin is a pancreatic hormone involved in the physiological regulation of satiety, gastric emptying, and nutrient intake.
The combination brings together compounds associated with incretin, glucagon, and amylin-related signaling. However, research on each individual compound should not be interpreted as establishing the safety, efficacy, or pharmacological behavior of this specific combined formulation.
Two Peptides. Distinct Signaling Pathways.
The individual components interact with different hormonal receptor systems. These mechanisms are studied for their roles in endocrine communication, appetite-related signaling, and metabolic homeostasis.
GIP Receptor Signaling
GIP receptor activation participates in glucose-dependent insulin secretion and nutrient-responsive pancreatic endocrine signaling.
GLP-1 Receptor Signaling
GLP-1 receptor activity influences insulin secretion, glucagon regulation, gastrointestinal function, and central pathways involved in appetite.
Glucagon Receptor Signaling
Glucagon receptor activation participates in hepatic glucose metabolism, substrate utilization, and pathways involved in energy expenditure.
Amylin-Related Signaling
Cagrilintide acts through amylin-related receptor systems involved in satiety, meal-related signaling, and regulation of gastric emptying.
Research Applications
The individual components provide a basis for investigating several metabolic and neuroendocrine processes. The following topics represent areas of scientific interest rather than validated applications of the combined formulation.
Multi-Receptor Pharmacology
GIP, GLP-1, glucagon, and amylin-related receptor signaling and downstream cellular responses.
Glucose Homeostasis
Endocrine mechanisms influencing insulin secretion, glucagon activity, and glucose metabolism.
Satiety Signaling
Neuroendocrine pathways involved in meal-related signaling and physiological appetite regulation.
Energy Homeostasis
Hormonal signaling associated with nutrient utilization, energy balance, and metabolic adaptation.
Gastrointestinal Physiology
Incretin and amylin-associated mechanisms influencing gastric motility and nutrient processing.
Peptide Formulation Research
Analytical characterization, molecular stability, compatibility, and integrity of multi-peptide research formulations.
Scientific Background
Retatrutide Research
Retatrutide was developed by Eli Lilly and has been investigated in clinical trials involving metabolic conditions.
Its pharmacological profile includes GIP, GLP-1, and glucagon receptor agonism.
Cagrilintide Research
Cagrilintide was developed by Novo Nordisk and has been investigated as a long-acting amylin analog.
Clinical research has examined its relationship to appetite regulation, satiety, and metabolic physiology.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff AM, et al. New England Journal of Medicine. 2023;389:514–526.
View Scientific PublicationOnce-Weekly Cagrilintide for Weight Management in People with Overweight and Obesity
The Lancet. 2021;398:2160–2172.
View Scientific PublicationBlend Specifications
General information about the individual components and research formulation. Exact composition and analytical characteristics should be verified against batch-specific documentation.
Storage & Laboratory Handling
Multi-peptide research materials should be stored and handled in accordance with verified supplier specifications and applicable laboratory safety procedures.
The storage characteristics of individual peptides do not necessarily establish the stability or compatibility of a combined formulation.
Researchers should consult available batch-specific analytical documentation for component identity, purity, stability, and handling requirements.
For Laboratory Research Only
Retatrutide + Cagrilintide is presented as an independently supplied research formulation. The combination is not an FDA-approved pharmaceutical product.
Materials supplied by Titan Helix Biosciences are designated for laboratory research and analytical investigation only. Published findings involving either individual compound do not establish the safety, efficacy, purity, or pharmaceutical equivalence of the combined material.
Not for human or veterinary use. Not intended for administration, consumption, diagnosis, treatment, prevention, or cure of any disease.
Research materials should be handled only by appropriately qualified laboratory personnel in suitable research environments.